IP3R Modulation by Cancer Genes in Mesothelioma
Sponsor
KU Leuven (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT03558932
Collaborator
(none)
20
65
Study Details
Study Description
Brief Summary
Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
20 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
IP3R Modulation by Cancer Genes Bcl-2 & PKM2 in Mesothelioma
Anticipated Study Start Date
:
Jan 1, 2019
Anticipated Primary Completion Date
:
Dec 1, 2023
Anticipated Study Completion Date
:
Jun 1, 2024
Outcome Measures
Primary Outcome Measures
- Pleural biopsy [5 years]
Biopsy
Other Outcome Measures
- Immunoblotting [5 years]
biopsy
- Cytometric analysis (FACS-based approaches) [5 years]
biopsy
- Live cell imaging for Ca2+-signaling [5 years]
biopsy
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 89 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
suspicion of mesothelioma
-
referral for diagnostic thoracoscopy
Exclusion Criteria:
- contra-indication for thoracoscopy
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- KU Leuven
Investigators
- Principal Investigator: Jonas Yserbyt, Catholic university Leuven
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Yserbyt Jonas,
Principal Investigator,
KU Leuven
ClinicalTrials.gov Identifier:
NCT03558932
Other Study ID Numbers:
- IP3mesov1
First Posted:
Jun 15, 2018
Last Update Posted:
Jun 15, 2018
Last Verified:
Jun 1, 2018
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: